

Ipsogen presents breast cancer biomarker results at the upcoming ECCO 13, the European Cancer Conference

Marseille, France, October 13, 2005 – Ipsogen SAS, the French cancer diagnostics company, announced today that its latest breast cancer program results had been selected for presentation in a symposium session at the ECCO 13 congress, Europe's pre-eminent cancer research conference, held in Paris from October 30 to November 03.

The abstract titled "Utilisation of microarray technology to refine molecular classes and improve clinical management of breast cancer," has been selected by the ECCO 13 Scientific Committee for oral presentation in the Proffered paper session "Molecular characterization of breast cancer and its clinical implications" which will be held on Thursday, 03 November, 2005.

The results concern several gene expression signatures refining molecular classes of breast cancer. Utilisation of these signatures together with standard clinical parameters provides a unique combination discriminating patients responding to standard anthracycline chemotherapy. The test was validated in an independent cohort with patient samples from a multicentric clinical trial. The study represents part of a research program Ipsogen is conducting with FNCLCC, Institut Paoli-Calmettes (Marseille, France) and other major cancer centres.

Based on these findings and ongoing clinical studies, Ipsogen believes there is potential for applying this test to identify patients, at diagnosis, with favorable outcome under standard anthracyclines chemotherapy to avoid unnecessary chemotherapy intensification.

About Ipsogen

IPSOGEN is a biotechnology company utilising advanced technologies to analyse gene expression and to improve disease management of cancers. IPSOGEN addresses two main markets: (i) The molecular diagnosis of cancer (i.e.; leukaemia, lymphomas, breast cancer, colon cancer) to provide innovative diagnostic tools to clinical centres; (ii) the optimisation of cancer drug development, to provide pharmaceutical companies with high value information at the pre-clinical and clinical stages, and accelerate drug development through biomarker identification and validation. Headquartered in Marseille, France, IPSOGEN has global partnerships and markets its products worldwide.

This press release contains "forward-looking statements" as defined in the US Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Ipsogen SAS does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the business of Ipsogen SAS, among others, the extent to which Ipsogen's technology platform can be used in large scale gene expression analysis, uncertainty of market acceptance of Ipsogen's technologies or ability to compete against existing technologies.

CONTACTS

Ipsogen: Tel +33 4 91293090 - infos@ipsogen.com



PRESS RELEASE

Global Headquarters

Ipsogen
Luminy Biotech Entreprises
Case 923 - 163 Ave de Luminy
13288 Marseille
France

Tel: +33 4 91 29 30 90
Fax: +33 4 91 29 30 99

infos@ipsogen.com

North America - Oncodiagnostics

Ipsogen, Inc
83 Maple Avenue
Windsor
Connecticut 06095
USA

Tel: +1 860 298 0234
Fax: +1 860 298 8586

infos@ipsogen.com